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Amyloid-b peptides (Ab) fibrillation is the hallmark of Alzheimer's disease (AD). However, it has been
challenging to discover potent agents in order to inhibit Ab fibrillation. Herein, we demonstrated the
effect of resorcinarene on inhibiting Ab fibrillation in vitro via experimental and computational methods.
Ab were incubated with different concentrations of resorcinarene so as to monitor the kinetics by using
thioflavin T binding assay. The results, which were further confirmed by far-UV CD spectroscopy and
atomic force microscopy, strongly indicated that the higher concentration of resorcinarene, the more
effective the inhibition of Ab fibrillation. A cytotoxicity study showed that when sea urchin embryos were
exposed to the resorcinarene, the majority survived due to the resorcinarene low toxicity. In addition,
when the resorcinarene was added, the formation of toxic Ab 42 species was delayed. Computational
studies of Ab fibrillation, including docking simulations and MD simulations, illustrated that the
interaction between inhibitor resorcinarene and Ab is driven by the non-polar interactions. These studies
display a novel strategy for the exploration of promising antiamyloiddogenic agents for AD treatments.Introduction
Alzheimer's disease (AD), the most common form of dementia,
causes progressive memory loss, behavior, and thinking prob-
lems.1,2 It has become a major threat for human beings around
the globe. Approximately 24.3 million people suffer from AD in
the world nowadays.2,3 In accordance with a recent report,4 the
number of the AD patients is expected to increase up to 81.1
million by 2040. Over the past 30 years, the etiology of the
disease has been attributed to the accumulation of the extra-
cellular plaques, which are mainly composed of amyloid-
b peptides (Ab), and intracellular tangles formed by tau
proteins.5,6 Much scientic research7–12 has proven that
sequentially cleavage of amyloid precursor protein (APP) by
BACE1 and b- and g-secretases can produce Ab monomer, and
the aggregation of Ab monomer into amyloid brils is strongly
associated with AD.13 In other words, Ab plays a central role in
the pathogenesis of AD. Both Ab 42 and Ab 40 are primary
isoforms of Ab, where Ab 42 is considered as the most toxic
form,14 and Ab 40 is the most abundant form.15 The develop-
ment of therapeutic agents targeting upstream secretases hadnter, University of Miami, Coral Gables,
u
y, University of California, Los Angeles,
.ucla.edu
niversity of Miami, Coral Gables, Florida
e los Andes, Cr. 1 No. 18A 10, Bogota
tion (ESI) available. See DOI:
hemistry 2017been unsuccessful.16 Thus the development of an inhibitor for
early stage Ab brillation could be a promising treatment
of AD.17
The major Ab contains 40 or 42 amino acids with residues
from 18 to 42 forming two parallel b sheets.18 Signicant efforts
and progress have gone into developing new amyloid brilla-
tion inhibitors. Ab brillation inhibitors are mainly designed in
two different ways: peptides or peptide mimetics19–23 and
organic compounds.10,24–27 However, the challenge to design
small molecules for Ab brillation is because protein–protein
interaction regions, approximately 20 nm2, are larger than the
protein-small molecule interaction regions which are around
3–10 nm2.28 Most small molecules, therefore, cannot afford
adequate steric hindrance to prevent the aggregation. Supra-
molecular strategy to block the aggregation process exhibits
another option for potent AD therapies. Lee et al. have
demonstrated such a strategy by using cucurbit[7]uril (CB[7]).29
However, the efficiency of the designed inhibitor is low. More
inhibitors – the reported lowest effective concentration ratio of
the inhibitor to Ab 42 is approximately 100 – to prevent amyloid
brillation are needed (Table S1†). In addition to less powerful
performance on blocking Ab aggregation, the cytotoxicity of Ab
42 brils cannot be delayed or inhibited by most other designed
inhibitors (Table S1†). It is, thus, in dire need to develop
inhibitors with sufficient potency to delay the onset of Ab
brillation and cytotoxicity of Ab 42.
The utility of resorcinarene has expanded greatly in the eld
of supramolecular chemistry and biochemistry.30–32 Not only the
semi-rigid structure and the p-electron rich cavity, but also the
hydrogen bonding sites of the molecule, provide an excellent
platform for the host–guest complexation.33,34 TheseChem. Sci., 2017, 8, 2003–2009 | 2003
Fig. 1 A schematic overview in vitro study of Ab fibrillation, which
includes the conformational transition from monomer to partially
folded intermediate or oligomer to mature fibrils.
Scheme 1 The structure of resorcinarene.
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View Article Onlinecompounds can be functionalized in diverse manners for
different applications, such as recognition of amino acids as
well as delivery tool in pharmacology.35–37 Inspired by such vital
applications in host–guest chemistry, we turned to the func-
tionalized resorcinarene as a potential strategy towards the
inhibition of Ab amyloid brillation for the rst time. Fig. 1
shows the Ab brillation pathway, where the partial denatur-
ation of the peptide monomer initiates the brillation route.
The denatured monomers self-assemble into oligomers and in
turn form brils via protobril formation. In a set of sequential
events, resorcinarene is expected to interact with Ab in a way
that increases the steric hindrance for bril aggregation and
abolishes the Ab brillation process which may delay the toxic
Ab 42 as well. Herein, we studied such a hypothesis by experi-
mental method, including thioavin T (ThT) binding assay,
circular dichroism spectroscopy (CD), atomic force microscopy
(AFM), and cytotoxicity assay, as well as theoretical approach
using docking calculations and MD simulations. These results
demonstrate a great potential application of resorcinarene in
retarding Ab brillation, and propose a new possibility for
further optimization of the inhibitor design. In particular,
resorcinarene as a delivery system with recognition and
encapsulation properties will emerge as a promising agent for
therapies of Alzheimer's disease.
Experimental section
Synthesis of resorcinarene
The resorcinarene was prepared according to our previous
published literature procedures.38 All characterizations,
including NMR, mass-spec, and X-ray crystallography, are
consistent with previous reported results. Briey, the resorci-
narene precursor was added to a solution which contained2004 | Chem. Sci., 2017, 8, 2003–2009formaldehyde, sodium sulde, and water, and stirred for 4 h at
90–95 C. The mixture was cooled down to room temperature,
and neutralized with hydrochloric acid. Acetonitrile was added
to precipitate sulfonated resorcinarene. Finally, the resulting
product 1 (Scheme 1) was recrystallized and washed in the same
solvent acetonitrile.Thioavin T (ThT) uorescence assay
The kinetics of Ab 42 and Ab 40 brillation can be characterized
by the uorescence increase of bril-specic dye of thioavin T
(ThT). To accomplish this, different concentrations of resorci-
narene, including the ratio of peptides to the resorcinarene at
1 : 0, 1 : 0.1, 1 : 1, and 1 : 5, were prepared for examination. At
rst, Ab 42 and Ab 40 were dissolved in 1,1,1,3,3,3-hexa-
uoroisopropanol to stabilize the a-helix structure of the
peptides. Aer evacuating the solvent, the solution was ltered
through a 0.2 mm membrane to remove the pre-brils. Different
concentrations of resorcinarene were added to 10 mM Ab in
25 mM PBS buffer solution (pH 7.4), respectively. Thereaer, the
mixture were incubated at 37 C, and aliquots of incubation
solutions at different time points were collected and then diluted
two times into ThT solution (25 mMThT in 25mMPBS buffer, pH
7.6). ThT uorescence was measured by a uorescence spectro-
photometer (LS-55, Perkin Elmer) at 25 C with a slit width of 5
nm for both excitation and emission. ThT emission was moni-
tored at 480 nm with the excitation at 440 nm.Circular dichroism (CD) spectroscopy
To gain insights into the effects of resorcinarene on the confor-
mational transition of Ab, far-UV CD spectroscopy (JASCO J-810)
were utilized tomonitor the secondary structure of Ab over time.39
Similar to the uorescence characterization, aliquots of incuba-
tion solutions described above were collected for CD spectra as
well. The spectra was recorded between 190 and 260 nm at room
temperature by a 2 mm optical path length quartz cell.Atomic force microscopy (AFM)
AFM images of samples withdrawn at different incubation
times can be studied to directly observe and monitor the
formation of brils. Tapping mode was used to observe
morphologies during the brillation process. The cantilever has
a resonance frequency of approximately 170 kHz with typicalThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineforce constant of 7.5 N m1. To scan the AFM images, aliquots
of samples withdrawn at different incubation times were
diluted with pure water, drop-coated on a freshly cleaved mica
surface, and allowed to dry for at least 1 h.
Cytotoxicity assay
Toxicity tests were performed in a new 24-well cell culture plate.
In each well, health fertilized eggs were incubated in 2 ml
control sea water or 2 ml dilution of 1 in sea water. For the 1
cytotoxicity test, the plate with fertilized eggs (Strongylocentrotus
purpuratus sea urchins) was incubated at 15 C for 48 hours
until they reach prism stage embryos. Ab 42 brils and different
Ab 42–1 complex were collected from incubated solutions. The
plate with fertilized egg (Lytechinus variegatus sea urchins) to
test the inhibiting effect of 1 on Ab 42 toxic species were per-
formed at room temperature for 24 hours until they reach prism
stage embryos. 100 of embryos were examined and rate of
embryo with normal development was calculated. Each experi-
ment was repeated with similar results. The error bars indicate
the standard error of the mean.
Ligand docking and molecular dynamics simulations
Possible binding modes of the resorcinarene to Ab 42 amyloid
brils were simulated using Potential Energy Landscape
Explorer web-server (PELE: http://pele.bsc.es/pele.wt).40 We
hypothesized that the resorcinarene can bind to the ends of the
lament and delay the amyloid ber growth by interfering the
monomer addition. Accordingly, two most populated confor-
mations from the PELE simulations with the ligand bound on
the top or the bottom of the lament were selected for the initial
congurations of the subsequent molecular dynamics simula-
tions. Molecular dynamics (MD) simulations of the ligand
bound amyloid brils were carried out using Amber14 so-
ware.41 The molecular mechanics parameters of the resorci-
narene was prepared using the Generalized Amber Force Fields
(GAFF).42 Atomic partial charges of the ligand were computed
using the AM1-BCC charge model embedded in the ante-
chamber program (Table S2†). The amyloid lament was
modelled using the AmberFF14SB force elds.43 The MD
simulations were initiated from the two most populated struc-
tures found from the PELE simulations. Each initial structure
was solvated in an octahedral box lled with TIP3P water
molecules, where the solute molecule has 11 A˚ margin from the
solvation boundary. Counter ions were added to guarantee the
charge neutrality. Each solvated system was equilibrated at 300
K for 6 ns, while keeping positions of all carbon atoms at initial
values. 100 ns production runs were followed, while restraining
alpha carbons of the lament at initial positions using weak
harmonic potentials (spring constant was 0.1 kcal mol1 A˚2).
Results and discussion
Inhibitory effect of resorcinarene on Ab brillation
The cationic benzothiazole dye, thioavin T (ThT), is well
known for its specic staining of amyloid brils, which
enhances emission uorescence. Fig. 2a shows the aggregationThis journal is © The Royal Society of Chemistry 2017kinetics of Ab bril formation at different concentrations of 1 by
the time dependent ThT uorescence assay. When incubating
10 mM Ab 42 alone, the ThT uorescent prole presented a lag
phase within 3 h, a slow elongation, and a saturated phase aer
3 days, while Ab 40 displayed a similar but faster brillation
process with an almost negligible lag phase which maintained
less than 1 h, an elongation phase within 3 h, and a saturated
phase aer 4 h. To evaluate the inhibition activity of 1 against
Ab brillation, Ab were present with different concentrations of
1 at the ratio of the resorcinarene to peptides of 0.1, 1, and 5,
respectively. At a Ab 42/1 ratio of 0.1, suppression of Ab 42
aggregation was observed. The elongation phase did not start
until incubating for 12 h. In contrast to this, it took Ab 42 3 h to
enter the same phase in the absence of 1. Adding more 1, the
uorescent intensity decreased by over 50% at the plateau. At Ab
42/1 ratio of 5, almost no brils were observed as evidenced by
the nearly at curve comparing to others. Overall, ThT proles
demonstrated that 1 inhibited Ab 42 brillation in a dose
dependent manner. 1 displayed a similar but more effectively
inhibition on Ab 40. 1 began to exhibit inhibition effect at Ab 40/
1 ratio of 0.1. When the Ab 40/1 ratio increased up to 1, the lag
phase period extended to approximately 4 h. If the concentra-
tion of 1 was further increased, 1 showed a stronger effect of
brillation inhibition, which retained active for 5 days. As
control experiments, resorcinarene was incubated alone at
37 C for 24 h, and the uorescence spectra of not only resor-
cinarene (Fig. S1†), also resorcinarene with 20 mMThT (Fig. S2†)
showed no disturb towards ThT assay tests above. To note, it is
surprising to observe that Ab 40 aggregated faster than Ab 42. It
may attribute to the protein purity since impure protein tends to
aggregate more slowly. However, in accordance with Table S1†
and results above, 1 exhibited excellent potential for effectively
inhibiting both Ab 42 and Ab 40 brillation. The other reason
leading to the faster Ab 40 aggregation might be that the
prepared amyloid-b peptides may contain seeds which can
accelerate the brillation process.44–46 To further conrm our
hypothesis, we carried out additional series of measurements
with regard to the aggregation of kinetics of Ab 42 and 40.
Preformed brils (seeds)47 were added to Ab 42 and Ab 40 at the
beginning of incubation, respectively. By recording ThT assay of
aggregation kinetics, the lag phase time of both amyloid-
b peptides with additional seeds was found to decrease
comparing to that without added seeds. In other words, both Ab
42 and Ab 40 with additional seeds aggregate faster than those
without seeds.
The Ab peptides are mainly random coil or a-helical in the
native conformation. They undergo a conversion to b-strand
during the bril formation, which is consistent with ThT assay
examination. To attain a clear perception of the effect of 1 on
the conformational conversion of Ab 42 and 40 upon aggrega-
tion, far-UV CD spectroscopy was employed to monitor the
secondary structure of the Ab peptides over time (Fig. 2b).
Aliquots of Ab 42 and 40 in the absence and presence of
inhibitor were collected for CD spectra at different time,
respectively. Even though peptides were incubated in PBS buffer
which has an inuence on the CD spectra, the spectra obtained
is still distinguishable. As shown in Fig. 2b, Ab 42 alone atChem. Sci., 2017, 8, 2003–2009 | 2005
Fig. 2 (a) Kinetics of 10 mMof Ab 42 and Ab 40 fibrillation: fluorescence intensity of thioflavin T (ThT) at 485 nm as a function of incubation time at
37 C in 25 mM PBS, pH 7.4 with the ratio of Ab to 1 at 1 : 0, 1 : 0.1, 1 : 1, and 1 : 5, respectively. The final concentration was a 2-fold dilution with
20 mM ThT. Baseline was corrected against the spectra of 1 (Fig. S2†). The ThT fluorescence was obtained for three repeats of each sample. The
error bars indicate the standard error of the mean. (b) Far-UV circular dichroism spectra of 10 mM Ab 42 alone (top panel) in 25 mM pH¼ 7.4 PBS
at 0, 12, 48, 72 h, and 10 mM Ab 42 incubated with 10 mM 1 (bottom panel), in 25 mM pH ¼ 7.4 PBS at 0, 24, 48, 96 h. AFM images (size: 2.5  2.5
mm) of 10 mM Ab 42 incubated at 37 C in 25 mM PBS, pH 7.4 with (c) 0 mM, (d) 1 mM, and (e) 10 mM 1, respectively.
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View Article Onlineincubation time 0 had a negative band at around 197 nm,
indicating that the initial secondary structure of Ab 42 adopted
a random coil form. Aer incubating 12 hours, this peak
diminished and shied slightly to approximately 200 nm, sug-
gesting the conformational change of Ab 42. Upon peptides
aggregation for 48 hours, a negative valley appeared at 213 nm,
which is assigned to b sheet of mature peptide bril. When
present with 10 mM 1, Ab 42 showed a similar structure transi-
tion with adopting mainly random coil conformations as evi-
denced from Fig. 2b. However, Ab 42 did not completely convert
to b sheet conformation even aer incubating 96 hours
comparing to the study of Ab 42 in the absence of 1. That is, 1
can potentially delay the conformational transition of Ab 42. In
the case of Ab 40, Fig. S5† showed a mixture of random coil,
b sheet, and b turn forms. Upon peptide aggregation, bands2006 | Chem. Sci., 2017, 8, 2003–2009shrink demonstrating conformational change severely where
a signicant decrease in the negative absorption around 200
nm. The nal content of b strand conformers at 4 h was much
more than that of initial Ab 40. In the presence of 1, it displayed
a similar random coil dominated conformations, but under-
going no transition with 24 h incubation, suggesting a delay of
brillation process (Fig. S6†). It can be concluded that the
inhibitory effect of 1 on conformational transition of Ab
aggregation from random coils to b strand.
To directly observe andmonitor the formation of these Ab 40
and 42 brils, AFM images were obtained in the absence and
presence of 1. The inhibition effect of 1 on Ab peptides bril-
lation is consistent with the previous observations. As illus-
trated in Fig. 2c, Ab 42 brils were apparent aer 72 h
incubation in the absence of 1, whereas when present with 1,This journal is © The Royal Society of Chemistry 2017
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View Article Onlineespecially with higher concentration, no long brils showed up
during the incubation. Ab 40 went through a similar brillation
process with a higher rate. Fibrils can be observed clearly only
aer 24 h incubation (Fig. S7†), in contrast to the fact that no
long brils but a few protobrils were recognized when incu-
bating with the inhibitor. To further conrm the contents of the
ThT endpoint samples, a pellet assay with an SDS-PAGE gel was
prepared.47 Fig. S4† showed that brils from the solution
without 1 are much larger than that with 1, which again reveals
that 1 can retard the aggregation of both amyloid-b peptides.
To note, all the tested Ab and resorcinarene mixtures con-
tained the same amount of Ab, and any increase in the uo-
rescent intensity from ThT assay prole may indicate more
brils were formed. It is interesting to observe that the nal ThT
intensity of resorcinarene mixed Ab solution decreased and
stabilized much lower than that of Ab alone, meaning less
brils were produced. The amyloid bril formation is a multi-
stage process that depends on the formation of small oligo-
meric species.9,48,49 With regard to the inhibition effect, we
speculate that resorcinarene interact with Ab lament at early
stage. The bound resorcinarene impede inter oligomers asso-
ciation by steric hindrance and delay the onset of bril growth.
The hypothesis is in accordance with CD and AFM study where
Ab brils were apparent in the absence of resorcinarene while
a few oligomers were formed in the presence of the inhibitor.Fig. 3 (a) Cytotoxicity test of resorcinarene to seaurchin embryos. (b)
The inhibitory effect of resorcinarene on the cytotoxicity of Ab 42
fibrils at different molar ratios of Ab 42 to resorcinarene.Cytotoxicity test of resorcinarene to sea urchin embryos
The effective inhibition of Ab bril formation by 1 suggests the
potential capability of 1 for therapy of AD application. A series of
cell viability tests were conducted to evaluate the cytotoxicity of
1 in the cellulous environment in which sea urchin embryos
were selected as a model system due to its extremely sensitive to
hazardous materials. Also sea urchin embryos have been widely
used for static acute toxicity of many chemicals test. Strong-
ylocentrotus purpuratus sea urchins (Marinus Scientic, Long
Beach, CA) were utilized in this study to test the toxicity of 1, and
adult animals with ripe gonads were used to collect gametes.
Fresh eggs were washed for 3 times with cold ltered articial
sea water and mixed with sperm to examine fertilization rate.
Only eggs with a fertilization rate greater than 95% were used
for the toxicity tests. Three biological replicates using three
individual male–female pairings were performed. Fig. 3a
showed 90% of embryos retain a normal morphology aer 20 h
of incubation with the presence of 20 mg ml1 1, in which
concentration already exhibited signicant effect on inhibition
of Ab brillation, indicating low cytotoxicity of 1 to cells.
Unfortunately, since sea urchins are extremely sensitive to
invading materials, when the concentration of 1 increasing up
to 1000 mM, most of the cells failed to survive under the incu-
bation environment. The effective inhibition of Ab 42 cytotox-
icity by 1 can suggest potential utility for therapeutic
applications. A series of cell viability tests were performed to
measure such effects induced by 1. Pure Ab 42 bril reduced the
viability of sea urchins cells (Lytechinus variegatus) in normal
forms to 0%, whereas the Ab 42–1 complex delayed the forma-
tion of Ab 42 toxic species, where the rate of normal embryosThis journal is © The Royal Society of Chemistry 2017increased to 81% with 50 mM 1 (Fig. 3b). In addition to the
normal form of sea urchin cells, there exist some cells alive but
unable to swim. In Fig. S8,† 92% of embryos are alive but in
abnormal forms when present with 10 mM pure Ab 42 brils.
Applying more 1, the rate decreased, which indicated the
reducing toxicity of Ab 42 brils induced by 1.Resorcinarene binds to the top and the bottom of the Ab 42
lament
The detailed interactions between the resorcinarene and the
amyloid lament were studied using molecular docking and
molecular dynamics (MD) simulations. The MD simulations
were initiated with bound resorcinarene on the top or the
bottom of the amyloid bril (Fig. S6†). The bound conforma-
tions were identied from the results of the docking simula-
tions using the PELE soware. Fig. 4 shows two of the binding
modes of the resorcinarene resulting from the 100 ns MD
simulations. Aer 80 ns of MD simulations, the root-mean-
squared deviation (RMSD) of all heavy atoms of the bound
resorcinarene converged to <3.0 A˚ from the last conguration at
100 ns. Of note, the RMSD to the initial docked conformation
increased to >4.0 A˚ as MD simulation progressed, that suggests
a conformational relaxation took place during the course of MD
simulations. The solvent accessible surface area of the ligand-Chem. Sci., 2017, 8, 2003–2009 | 2007
Fig. 4 Predicted interactions of the resorcinearene and the Ab 42
amyloid filament. Two of the relatively stable interactions patterns are
predicted using the PELE and the MD simulations: (a) and (b). The last
snapshots from the MD simulations are illustrated. Root-mean-
squared deviations from the initial docked structure (blue), the last
configuration of theMD simulation (red), and the buried surface area of
the ligand–protein interface (orange) of each are plotted on bottom.
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View Article Onlineamyloid ber complex was always smaller than that of the iso-
lated ligand and amyloid ber. The nding indicates the ligand
is always in contact with the amyloid bril. The averaged buried
solvent accessible surface area (DSASA) over the last 20 ns was
767 A˚2 for the mode 1 and 845 A˚2 for the mode 2. We also
computed surface area dependent non-polar hydrophobic
energies using the formula proposed by Honig's group: Ehphobic
¼ g  DSASA, where g is 0.05 kcal mol1 A˚2.50 The computed
non-polar hydrophobic energies averaged over the last 30 nsMD
simulations are 38 kcal mol1 and 42 kcal mol1 for the
mode 1 and the mode 2, respectively. The amount of the non-
polar interaction energies are sufficient to overcome trans-
lational–rotational entropic penalty that is +26 kcal mol1 less
favorable for binding. We analyzed favorable interactions across
the interface of the bound resorcinarene and the amyloid bril.
In the rst binding mode (Fig. 4a), thiomethyl groups of the
resorcinarene were in contact with methyl group of Ala21 in the
amyloid bilayer interface. Also a sp2 carbon of resorcinol is in
contact with the sidechain of Leu34 and Phe19. Likewise, in the
second binding mode (Fig. 4b), thiomethyl groups make non-
polar contacts with Val36 and Leu34. A sp2 carbon of resorcinol
is in contact with the sidechain of Phe19.
Conclusions
In summary, the effective inhibition of Ab brillation by
resorcinarene was demonstrated in vitro by the ThT assay, the
circular dichroism spectroscopy, and the atomic force micros-
copy. Using the computational methods, including docking
simulations and MD simulations, the binding of resorcinarene
was shown to be mediated by non-polar interactions. The
advantages that could arise with resorcinarene that is signi-
cantly better than others at Ab brillation inhibition include: (1)
lower concentration required to block Ab aggregation, (2) low
toxicity to seaurchin embryo, which is extremely sensitive to2008 | Chem. Sci., 2017, 8, 2003–2009hazardous materials, and (3) the formation of Ab toxic species
can be delayed, which all make our designed inhibitor a prom-
ising candidate for the treatment of Alzheimer's disease. To our
knowledge, it is the rst time for the application of resorci-
narene on the Ab brillation. Thus, with the remarkable
inhibitory function towards Ab brillation and its capability in
encapsulation, resorcinarene presented in this work shows
great potential to be applied in pharmaceutical industry or
other areas for the treatment of Alzheimer's disease.
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